| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| C9418 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| J9070 | Cyclophosphamide | Cyclophosphamide | 100 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1984 | Apr 17, 2024 | No Longer Used | |
| NA | Cysteamine Bitartrate | Cystagon | 50mg, 150mg | Chemotherapy | Cystine-Depleting Agent | Yes | 1994 | In Use | ||||
| C9078 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDX 4/6 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | |
| J9390 | Vinorelbine | Navelbine | 10 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1994 | Jan 1, 1996 | In Use | ||
| NA | Avapritinib | Ayvakit | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| J9046 | Bortezomib (Dr Reddy) | Bortezomib (Dr Reddy) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2022 | Dec 21, 2022 | In Use | ||
| C9081 | Idecabtagene vicleucel | Abecma | up to 460000000 | Immunotherapy | CAR-T | BCMA | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| J9051 | Bortezomib (Maia) | Bortezomib | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | Yes | 2022 | Aug 28, 2023 | In Use | ||
| NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
| J8530 | Cyclophosphamide | Cyclophosphamide oral | 25 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | Jan 1, 1995 | In Use | ||
| NA | Lapatinib | Tykerb | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Yes | 2007 | In Use | |||
| NA | Lenalidomide | Revlimid | 5 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2005 | In Use | |||
| J2650 | Prednisolone Acetate | Flo-Pred [DSC], Millipred, Millipred DP, Orapred ODT, Orapred [DSC], Pediapred, Prednisone Intensol, Veripred 20, Prednisolone Sodium Phosphate | 1 ml | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1955 | Jan 1, 1997 | In Use | ||
| S0170 | Anastrozole | Arimidex | 1mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | Jan 1, 2002 | In Use | |||
| J9307 | Pralatrexate | Folotyn | 1 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2009 | Jan 1, 2011 | In Use | ||
| J7510 | Prednisolone | Flo-Pred [DSC], Millipred, Millipred DP, Orapred ODT, Orapred [DSC], Pediapred, Prednisone Intensol, Veripred 20, Prednisolone Sodium Phosphate | 5 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1955 | Jan 1, 2000 | In Use | ||
| J9310 | Rituximab | Rituxan | 100 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 1997 | Jan 1, 1999 | In Use | ||
| J3121 | Testosterone Enanthate | Testosterone Enanthate | 1 mg | Hormonal Therapy | Androgen | No | 1953 | Jan 1, 2015 | In Use | |||
| J9329 | Tislelizumab-jsgr | Tevimbra | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2024 | Sep 11, 2024 | In Use | ||
| Q0166 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1993 | Jan 1, 2009 | In Use | ||
| NA | oxymetholone | Anadrol-50 | 50 mg | Ancillary Therapy | Anabolic Steroid | Androgen | Yes | 1972 | In Use | |||
| NA | sonidegib | odozmo | 200 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2015 | In Use | |||
| J9015 | Aldesleukin | Proleukin | Per single vial (1 vial = 22 million IU) | Immunotherapy | Cytokine | Interleukin-2 | No | 1992 | Oct 1, 1996 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home